EBM

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Web-only table
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Loder, E. W
Right arrow Search for Related Content
PubMed
Right arrow Articles by Loder, E. W
Evidence-Based Medicine 2005; 10:83
© 2005 BMJ Publishing Group Ltd.


Therapeutics

Review: intravenous metoclopramide is better than placebo for reducing pain in acute migraine in the emergency department

Colman I, Brown MD, Innes GD, et al. Parenteral metoclopramide for acute migraine: meta-analysis of randomised controlled trials. BMJ 2004;329:1369–73.[Abstract/Free Full Text]

Q In patients with acute migraine, is metoclopramide more effective than a control intervention for reducing symptoms?

Clinical impact ratings GP/FP/Primary care ******{star} Neurology ******{star} Emergency medicine ****{star}{star}{star}

Key Words: antiemetics • metoclopramide • migraine

The first 150 words of the full text of this article appear below.

METHODS
{ebmcmptrbooks.f1}Data sources: Medline; EMBASE/Excerpta Medica; LILACS; CINAHL; Cochrane Central Register of Controlled Trials; neurology, headache, and emergency medicine conference proceedings (1998–2004); clinical practice guidelines; websites; theses or dissertations; reference lists; and experts in the field.

{ebmmgnfyglas.f1}Study selection and assessment: randomised controlled trials (RCTs) that compared parenteral metoclopramide with placebo, other antiemetics [AEs], non-AEs, or other antimigraine [AM] regimens in adults with an acute migraine in an emergency department (ED) or headache clinic, and distinguished migraine from other types of headaches. Study quality was assessed.

{ebmruler.f1}Outcomes: complete relief of headache, significant reduction in headache pain (from moderate or severe to mild or none), and reduction in headache pain on the basis of a 10 cm visual analogue scale (VAS). Secondary outcomes included relapse of migraine within 48 hours of treatment, nausea, number of rescue drugs required, functional status, and adverse effects.

MAIN RESULTS
13 RCTs (n = 655) met the selection criteria. 7 . . . [Full text of this article]

Elizabeth W Loder, MD

Spaulding Hospital, Boston, Massachusetts, USA







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2005 by the BMJ Publishing Group Ltd.